THE NICKLES GROUP, LLC for AMGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1, One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. H.R. 946 / S. 1862, ORPHAN Cures Act. Issues related to the Most Favored Nation drug pricing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Health Issues HCR
Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Copyright/Patent/Trademark CPT
Monitored issues related to intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFF CHOUDHRY | — |
| GREG D'ANGELO | — |
Taxation/Internal Revenue Code TAX
H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act, and corporate taxes. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RACHEL JONES HENSLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.